GlassScriptPhysician profile
Alexander Williams
NPI 1073977310
$18,705.62
in general payments reported to CMS, 2019-2025
42 companies · $9,374 in 2025
The $9,374 reported for 2025 was more than what 90% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2021: $60.16 · 2022: $1,091 · 2023: $768 · 2024: $7,272 · 2025: $9,374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,235 · Food and Beverage: $7,601 · Travel and Lodging: $535 · Education: $42.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,235.00 |
| Food and Beverage | $7,601.02 |
| Travel and Lodging | $535.13 |
| Education | $42.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $4,647.60 | 2022-2025 | Strensiq |
| Neurocrine Biosciences, INC. | $3,340.64 | 2024-2025 | |
| Novo Nordisk INC | $2,683.80 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Kyowa Kirin, INC. | $1,217.08 | 2024-2025 | Crysvita |
| Lilly USA, LLC | $733.64 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $666.97 | 2023-2025 | Evenity, Prolia, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $593.90 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $471.85 | 2023-2025 | |
| Beta Bionics, INC. | $347.47 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Sanofi-Aventis U.S. LLC | $323.27 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $321.03 | 2023-2025 | Jardiance |
| Dexcom, INC. | $316.82 | 2021-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $280.98 | 2024-2025 | Korlym |
| Abbott Laboratories | $263.94 | 2023-2025 | Freestyle Libre 2 |
| Medtronic, INC. | $247.90 | 2024-2025 | Minimed 780g |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $204.23 | 2024-2025 | Xyosted |
| Radius Health, INC. | $190.81 | 2023-2025 | Tymlos |
| Abbvie INC. | $174.23 | 2023-2025 | Synthroid |
| Ibsa Pharma INC. | $165.35 | 2023-2025 | Licart, Tirosint, Tirosint |
| Amneal Pharmaceuticals LLC | $152.11 | 2023-2025 | Unithroid |
| Tandem Diabetes Care, INC. | $147.20 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Genentech USA, INC. | $140.78 | 2019 | |
| Recordati_rare_diseases_inc. | $138.13 | 2023-2025 | Isturisa, Signifor Lar |
| Xeris Pharmaceuticals, INC. | $123.46 | 2023-2025 | Gvoke Hypopen |
| Astellas Pharma US INC | $117.25 | 2024-2025 | Veozah |
| Ascendis Pharma Endocrinology INC | $112.47 | 2025 | Yorvipath |
| Mannkind Corporation | $69.05 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $67.41 | 2023-2024 | Crysvita, Crysvita |
| Sequel Med Tech, LLC | $67.00 | 2025 | Twiist |
| Madrigal Pharmaceuticals | $63.67 | 2025 | Rezdiffra |
| Globus Medical, INC. | $49.55 | 2025 | Senza |
| Nevro Corp. | $46.76 | 2023-2024 | Senza |
| Insulet Corporation | $31.63 | 2023-2024 | Omnipod |
| Boston Scientific Corporation | $29.17 | 2025 | General - Pain Management |
| Cardinal Health 414 LLC | $28.12 | 2024 | |
| Verity Pharmaceuticals INC. | $22.49 | 2025 | Tlando |
| Averitas Pharma INC. | $22.15 | 2025 | Qutenza |
| Regeneron Healthcare Solutions, INC. | $20.74 | 2024 | Evkeeza |
| Pfizer INC. | $18.27 | 2024 | |
| Halozyme INC | $15.95 | 2023 | |
| Avvisto Therapeutics, LLC | $15.77 | 2025 | Cycloset |
| Tolmar, INC. | $14.98 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.